See you all at $1 soon!
Sentiment: Strong Buy
Sept. 30, 2013, 8:58 a.m. EDT
Cardiac Biomarker ST2 Proves Far Superior To Galectin-3 In A Head-to-Head Study
Galectin-3 pales in comparison. ST2 provides the most accurate risk prediction for patients with heart failure, even improving discrimination when the two most-popular cardiac biomarkers, natriuretic peptides and high-sensitive troponin, are included.
As President and Chief Executive Officer at BG MEDICINE INC, Eric Bouvier made $2,756,775 in total compensation. Of this total $400,000 was received as a salary, $0 was received as a bonus, $2,356,775 was received in stock options, $0 was awarded as stock and $0 came from other types of compensation. This information is according to proxy statements filed for the 2012 fiscal year.
ST2 Assay is CE Marked and has received 510(k) clearance from the US FDA for use in risk stratification of chronic heart failure patients.
Sources of Liquidity
Our primary sources of liquidity include our cash balances, sales of our equity securities, product revenue from sales of the BGM Galectin-3 test, and service revenue from our research initiatives and collaborations and biomarker discovery and analysis services agreements, which we wound down in the fourth quarter of 2012. As of December 31, 2012, we had $12.8 million of cash, $390,000 of restricted cash from funding received under the HRP initiative, and working capital of $6.3 million.
Prior to our initial public offering in February 2011, our primary sources of liquidity were funds generated from our sale of shares of our preferred stock, debt financings, and cash receipts from our research and development collaborations and service agreements.
In 2011, we closed our initial public offering of 5,750,000 shares of our common stock. The net offering proceeds received by us, after deducting underwriting discounts and commissions and expenses incurred in connection with the offering, were approximately $34.8 million.
In 2012, we entered into a secured term loan facility with General Electric Capital Corporation and Comerica Bank and a term loan in the aggregate principal amount of $10.0 million was funded upon the closing of the transaction.
Over the period covered by this Management Discussion and Analysis, we have recognized product revenues of approximately $3.0 million and service revenues related to research and development initiatives and collaborations of approximately $2.2 million. From inception to date, service revenues have totaled approximately $48.3 million; however, we do not expect these revenues in 2013 and beyond to be significant.
In January 2013, we closed a follow-on underwritten public offering of 6,900,000 shares of our common stock, which included the sale of 900,000 shares pursuant to the underwriters' over-allotment option. The net offering proceeds received by us, after deducting underwriting discounts and commissi
I don't see much is there somewhere else I can see they own quite a bit of the stock?
RECENT INSIDER TRANSACTIONS ACTIVITY: BG MEDICINE
DATE NAME TRANSACTION NUM SHARES PRICE(S) VALUE
08/01/13 Mr. Stephane Bancel Grant 52,083 NA NA
06/12/13 Dr. Noubar B. Afeyan, PhD Grant 4,205 NA NA
06/12/13 Harrison M. Bains Grant 4,205 NA NA
06/12/13 Dr. Timothy Harris,PhD Grant 4,205 NA NA
06/12/13 Mr. Brian S. Posner Grant 4,205 NA NA
06/12/13 Dr. Stelios Papadopoulos,PhD Grant 4,205 NA NA
05/10/13 Mr. Paul Sohmer Grant 700,000 NA NA
05/01/13 Mr. Stephane Bancel Grant 39,473 NA NA
04/26/13 Ms. Anastasia Rader Grant 75,000 NA NA
04/26/13 Dr. Aram Adourian, PhD Grant 200,000 NA NA
01/30/13 Dr. Noubar B. Afeyan, PhD Purchase 2 Mil 2.00 4 Mil
01/30/13 Dr. Stelios Papadopoulos,PhD Purchase 250,000 2.00 500,000
12/10/12 Charles H. Abdalian,Jr Grant 140,000 NA NA
11/19/12 Mr. Brian S. Posner Purchase 10,000 1.17 11,650
11/15/12 Mr. Stephane Bancel Purchase 100,000 1.26 126,000
Just be careful here this thing could drop quite a bit if this is right
ST2 Proves Far Superior To Galectin-3
I've been burned too many times with these pumps and dumps I was doing my homework that's all! why aren't the inside is by now at these levels if it's such a good deal?
You say you own the stock prove it show me what you have make a copy of your buys that shouldn't take too long if you hold this position!
Very simple if you guys can't do that much how do we know if you really on the stock?
Waiting prove it If you really on the stock?
This guy was a real investor so simple you long are heard talking about buying buying buying you can't even show what you bought !
II read this post on other boards that you been hyping on If you're so the good at copying and pasting Why can't you copy and paste your buys that you have bought in this stock to us all jboy did!